You are here: Industry Insights > gilead

News List

Stealthy Insitro opens up—starting with Gilead deal worth up to $1.05B fiercebiotech
April 17, 2019
Daphne Koller’s Insitro launched last May with a blog post detailing an ambitious goal: to harness data and machine learning in the creation of a new approach to drug discovery.
In hiking prices, drugmakers show some signs of tempering increases PharmaSources/biopharmadive
March 26, 2019
In hiking prices, drugmakers show some signs of tempering increases
Louisiana's 'Netflix' deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck fiercepharma
March 08, 2019
States across the U.S. have taken on high drug prices with new laws, proposals and Medicaid rules, many of them unpopular with the pharma industry.
Glenmark Appoints New Innovation Company CEO contractpharma
March 07, 2019
Dr. Alessandro Riva will lead the new company, which will be a wholly-owned subsidiary of Glenmark and based in Paramus, NJ
Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPO pharmaphorum
March 07, 2019
It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership with MaxCyte, and Precision BioSciences filing for a $100 million IPO for its ‘off-the-shelf’ cancer cell therapies.
Gilead to help HIV patients ‘Age Positively’ with $17.6M in grants to 30 groups fiercepharma
March 07, 2019
The face of HIV is aging. This year, for the first time, more than half of people living with HIV in the U.S. will be older than 50.
Gilead to help HIV patients ‘Age Positively’ with $17.6M in grants to 30 groups fiercepharma
March 05, 2019
The face of HIV is aging. This year, for the first time, more than half of people living with HIV in the U.S. will be older than 50.
Trump's HIV pledge comes as Gilead pumps cash into Truvada for PrEP fiercepharma
February 24, 2019
Gilead is looking to eventually sub out Truvada for its newer HIV drug Descovy when it comes to pre-exposure prophylaxis. But in the meantime, it’s socking cash into promoting the older brand for PrEP.
Gilead NASH drug fails late stage trial pharmaphorum
February 13, 2019
Gilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial.
Supreme Court rebuffs appeals from Merck, Gilead in 2 high-profile drug battles fiercepharma
January 10, 2019
Monday was a good-news-bad-news day for Gilead Sciences at the U.S. Supreme Court, with the justices handing down multiple decisions about which appeals they would take up as they headed back to work after the holiday break.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page